24.10.2013
- Small But Mighty - Highly potent active ingredients (HPAPIs) are remarkably effective at small doses. Therapies including oncology, hormones, narcotics, musculoskeletal treatments...
25.04.2013
- In the first quarter 2013, Lonza's business performance was solid and in line with expectations. While the Specialty Ingredients market segment showed a good performance, the...
05.04.2013
- The Teva-Lonza Joint Venture issued the following statement today: The potential to develop, manufacture and market affordable, efficacious and safe biosimilars remains an area of...
25.03.2013
- Delays in developing copies of Roche's top-selling biotech drug are justifying the Swiss company's decision to stay out of biotech generics to focus on improved, patented versions...
14.03.2013
- Lonza Walkersville and Hyglos, a German biotech company, announced today that they have reached a mutually beneficial global settlement which includes a license agreement for...
20.02.2013
- The National Institutes of Health Center for Regenerative Medicine (NIH CRM) has awarded Lonza Walkersville a contract to generate induced pluripotent stem cells (iPSCs) for...
24.01.2013
- Swiss specialist chemicals supplier Lonza reported better than expected profits on Thursday and said it expects a further increase in sales and profits this year on the back of new...
16.01.2013
- Lonza, a leader in biological development and BaroFold, an protein technology developer, announced today a non-exclusive technology and license agreement whereby Lonza will...
